Daxor Corporation Awarded New U.S. Defense Health Agency Contract for Added Capabilities to Its Point-of-Care Blood Volume Analyzer

The Hematocrit Feature Will Be Integrated Into A Future Generation Blood Volume Analyzer (BVA)

Oak Ridge, TN, July 24, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that Daxor has received a $550K matching-fund extension from the U.S. Defense Health Agency (DHA) to its Phase II SBIR contract. This additional funding will support adding hematocrit measurement to a future generation blood volume analyzer. The upgrade eliminates the need for hematocrit testing from third-party devices to perform the BVA test.

Read more at globenewswire.com